![](/wp-content/uploads/2022/08/August-3-2022-Blast-Cover.png)
$599
Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGM
A series of cardiometabolic-related news items have been observed: Tandem (press release), Amarin (press release; slides), and Intercept (press release; slides) hosted their respective earnings calls; and Senseonics announced Anthem is now covering implantable CGMs, including Senseonics’s Eversense E3 CGM. Below, FENIX provides highlights and insights for the respective new items.